Anjali Singh

German biotech firm explores hospital-linked cell and gene therapy manufacturing in India while assessing long-term opportunities in regional CGT production, training and exports

EPAM bets on India as global co-innovation hub for AI-driven life sciences and healthcare expansion

Pharma leaders at BioAsia said AI is accelerating discovery and documentation, doubling pipelines at some firms, though its impact on clinical costs and timelines remains uneven

Global firms are scaling AI, life sciences and GCC operations in Hyderabad, backed by strong talent, pharma depth and policy support, with major investments announced around BioAsia this week

Sanofi has expanded its Hyderabad Global Capability Centre, raising capacity to 4,500 employees and strengthening India's position as a key hub for R&D, AI, digital innovation

Market-specific recovery patterns drove swings in overseas volumes in Q3

Hospital chain reports ₹193.7 crore net profit in Q3 FY26 amid one-time expense; hospital and diagnostics segments post revenue growth and margin expansion

Alkem Laboratories' devices arm to acquire controlling stake in Swiss cardiac implant maker, marking entry into global structural heart segment

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Automaker to invest ₹196 crore in expanding Mahindra Research Valley in Chennai, adding advanced R&D and testing facilities and creating 2,000 jobs this year

Doctors warn that heavy reliance on HbA1c for diabetes diagnosis in India may lead to under- or over-diagnosis due to high anaemia and kidney disease burden, urging multiparametric testing

India's EV retail market expanded in January 2026, with passenger vehicles and two-wheelers posting strong year-on-year growth amid rising demand, FADA data showed

The US-Bangladesh reciprocal trade pact is unlikely to materially affect India's auto and auto component exports, analysts say, despite tariff concessions and wider market access for Dhaka

French drugmaker to commit €15 million annually to SPC development and exports for cardiometabolic and venous diseases

Industry says approval delays, weak clinical trial infra holding back sector

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

India's auto component exporters may see relief under the interim US-India trade framework, but industry bodies say clarity on Section 232 tariffs and quota rules is needed to gauge gains

JK Tyre reported its highest-ever quarterly revenue in Q3 FY26 as volumes recovered and raw material costs eased, helping profits rebound sharply from a weak base last year

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market

India's second-largest pathology chain reported strong year-on-year profit growth in the December quarter, supported by higher test volumes, preventive care demand and specialised diagnostics